A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis（HLH）
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is a phase I study of TQ05105 tablets in subjects with Hemophagocytic
Lymphohistiocytosis.TQ05105 is a JAK2 inhibitors and can be used to treat JAK2 target-related
diseases. The activation of the JAK/STAT pathway is related to abnormal proliferation,
obstruction of apoptosis, and differentiation disorder of leukemia cells which is caused by
genetic abnormalities and viral infection.